Immix Biopharma (IMMX) Institutional Ownership $2.19 -0.14 (-6.01%) Closing price 04:00 PM EasternExtended Trading$2.27 +0.08 (+3.47%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Immix Biopharma (NASDAQ:IMMX)CurrentInstitutional OwnershipPercentage11.26%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$308.13KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$61.09K Get IMMX Insider Trade Alerts Want to know when executives and insiders are buying or selling Immix Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IMMX Institutional Buying and Selling by Quarter Immix Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025Velan Capital Investment Management LP25,000$52K0.1%N/A0.087% 7/17/2025 Tritonpoint Wealth LLC24,526$51K0.0%N/A0.088% 5/13/2025 Tocqueville Asset Management L.P.29,300$49K0.0%-23.5%0.105% 2/14/2025Jane Street Group LLC17,523$39K0.0%N/A0.064% 2/6/2025 SBI Securities Co. Ltd.17,500$38K0.0%N/A0.064% 1/13/2025 FNY Investment Advisers LLC28,750$63K0.0%N/A0.105% 11/16/2024 Geode Capital Management LLC150,082$224K0.0%+5.6%0.546% 10/22/2024 Private Advisor Group LLC34,325$51K0.0%-47.3%0.130% 8/16/2024Invst LLC27,000$57K0.0%N/A0.102% 8/12/2024 XTX Topco Ltd17,663$35K0.0%-66.2%0.067% Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 8/9/2024 Renaissance Technologies LLC154,685$306K0.0%-41.7%0.586% 8/7/2024 AIGH Capital Management LLC1,406,680$2.79M0.9%-9.5%5.326% 5/10/2024 Tocqueville Asset Management L.P.37,800$116K0.0%+89.0%0.143% 4/26/2024 Tritonpoint Wealth LLC24,526$75K0.0%N/A0.093% 2/7/2024 Jump Financial LLC18,500$128K0.0%N/A0.093% 2/6/2024 Private Advisor Group LLC99,775$690K0.0%N/A0.502% 2/1/2024 OLD National Bancorp IN10,000$69K0.0%N/A0.050% 1/30/2024Imprint Wealth LLC34,483$239K0.2%+49.4%0.174% 11/9/2023 Tocqueville Asset Management L.P.12,000$41K0.0%N/A0.061% 10/23/2023 Commonwealth Equity Services LLC28,855$99K0.0%+26.4%0.147% 7/28/2023 Koshinski Asset Management Inc.51,001$137K0.0%N/A0.339% 7/25/2023 UMB Bank n.a.72,639$195K0.0%-26.8%0.483% 4/11/2023 UMB Bank n.a.99,300$181K0.0%N/A0.714% 2/10/2023Murchinson Ltd.67,200$154K0.0%N/A0.482% 2/7/2023Lynwood Capital Management Inc.25,000$58K0.1%N/A0.179% 2/1/2023 Bank of Montreal Can15,000$36K0.0%N/A0.108% 5/11/2022InterOcean Capital Group LLC15,900$38K0.0%N/A0.115% 2/14/2022 Altium Capital Management LP122,388$436K0.1%N/A1.616% 2/14/2022Murchinson Ltd.695,600$2.48M0.2%N/A9.183% 2/9/2022 Context Capital Management LLC11,532$41K0.0%N/A0.152% 2/2/2022PVG Asset Management Corp20,000$71K0.3%N/A0.264% 2/1/2022Eidelman Virant Capital29,856$103K0.0%N/A0.394% (Data available from 1/1/2016 forward) IMMX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IMMX shares? During the previous two years, 16 institutional investors and hedge funds held shares of Immix Biopharma. The most heavily invested institutionals were AIGH Capital Management LLC ($2.79M), Renaissance Technologies LLC ($306K), Imprint Wealth LLC ($239K), Geode Capital Management LLC ($224K), Jump Financial LLC ($128K), Commonwealth Equity Services LLC ($99K), and OLD National Bancorp IN ($69K).Learn more on Immix Biopharma's institutional investors. What percentage of Immix Biopharma's stock is owned by institutional investors? 11.26% of Immix Biopharma's stock is owned by institutional investors. Learn more on IMMX's institutional investor holdings. Which institutional investors have been buying Immix Biopharma's stock? Of the 13 institutional investors that purchased Immix Biopharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Private Advisor Group LLC ($99.78K), Tritonpoint Wealth LLC ($49.05K), Tocqueville Asset Management L.P. ($29.80K), FNY Investment Advisers LLC ($28.75K), Invst LLC ($27K), Velan Capital Investment Management LP ($25K), and Jump Financial LLC ($18.50K). How much institutional buying is happening at Immix Biopharma? Institutional investors have bought a total of 148,253 shares in the last 24 months. This purchase volume represents approximately $308.13K in transactions. Which of Immix Biopharma's major shareholders have been selling company stock? The following institutional investors have sold Immix Biopharma stock in the last 24 months: Private Advisor Group LLC ($30.85K), and Tocqueville Asset Management L.P. ($9K). How much institutional selling is happening at Immix Biopharma? Institutional investors have sold a total of 39,850 shares in the last 24 months. This volume of shares sold represents approximately $61.09K in transactions. Related Companies Mereo BioPharma Group Institutional Ownership Humacyte Institutional Ownership Puma Biotechnology Institutional Ownership DBV Technologies Institutional Ownership Alpha Teknova Institutional Ownership Editas Medicine Institutional Ownership Prima BioMed Institutional Ownership Neumora Therapeutics Institutional Ownership Adherex Technologies Institutional Ownership scPharmaceuticals Institutional Ownership This page (NASDAQ:IMMX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.